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Abstract
The highly conserved YrdC domain-containing protein (YRDC) interacts with the well-described KEOPS complex, regulat-
ing specific tRNA modifications to ensure accurate protein synthesis. Previous studies have linked the KEOPS complex to a 
role in promoting telomere maintenance and controlling genome integrity. Here, we report on a newborn with a severe neo-
natal progeroid phenotype including generalized loss of subcutaneous fat, microcephaly, growth retardation, wrinkled skin, 
renal failure, and premature death at the age of 12 days. By trio whole-exome sequencing, we identified a novel homozygous 
missense mutation, c.662T > C, in YRDC affecting an evolutionary highly conserved amino acid (p.Ile221Thr). Functional 
characterization of patient-derived dermal fibroblasts revealed that this mutation impairs YRDC function and consequently 
results in reduced  t6A modifications of tRNAs. Furthermore, we established and performed a novel and highly sensitive 
3-D Q-FISH analysis based on single-telomere detection to investigate the impact of YRDC on telomere maintenance. This 
analysis revealed significant telomere shortening in YRDC-mutant cells. Moreover, single-cell RNA sequencing analysis 
of YRDC-mutant fibroblasts revealed significant transcriptome-wide changes in gene expression, specifically enriched for 
genes associated with processes involved in DNA repair. We next examined the DNA damage response of patient’s dermal 
fibroblasts and detected an increased susceptibility to genotoxic agents and a global DNA double-strand break repair defect. 
Thus, our data suggest that YRDC may affect the maintenance of genomic stability. Together, our findings indicate that bial-
lelic variants in YRDC result in a developmental disorder with progeroid features and might be linked to increased genomic 
instability and telomere shortening.
Introduction
Segmental progeroid syndromes are rare congenital disor-
ders characterized by signs and symptoms of premature or 
accelerated aging. Typical features of progeroid syndromes 
include, e.g., lipodystrophy, growth retardation, hair loss, 
brittle bones, atherosclerosis, and hearing loss. Several of 
these progeroid disorders show overlapping phenotypes, 
which makes specific clinical diagnosis often challenging. 
Most progeroid syndromes known so far belong to a very 
heterogeneous group of disorders caused by autosomal 
dominantly or recessively inherited mutations in a single 
gene. Yet identified cellular pathways and molecular patho-
mechanisms underlying premature aging mainly affect DNA 
damage repair processes, nuclear membrane dynamics, 
chromatin structure or transcription and, thereby, have an 
impact on various aspects of cell viability (Gordon et al. 
2014; Carrero et al. 2016). Genomic instability as well as 
telomere shortening have been identified as particularly 
relevant for aging-associated processes (Harley et al. 1990; 
Blackburn 1991; Lange 2005; Martínez and Blasco 2011). 
In many aspects, the molecular characteristics of progeroid 
syndromes seem to be similar to those of “physiological” 
aging. Therefore, studying conditions of premature aging 
will help to reveal unknown underlying causal mechanisms 
and to develop potentially new treatments for more frequent 
age-associated diseases (Lessel and Kubisch 2019).
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Previous studies suggest that YRDC (YrdC domain-
containing protein; OMIM#612276), the human homolog 
of yeast Sua5, contributes to various central cellular func-
tions. First, YRDC has been described to be necessary for 
adding specific tRNA modifications that are essential to 
ensure the accuracy of protein synthesis. YRDC in combi-
nation with the Kinase, Endopeptidase and Other Proteins 
of small Size (KEOPS) protein complex synthesizes the 
universally conserved threonylcarbamoylation of the N6 
nitrogen of the adenosine at the tRNA position 37  (t6A) 
(Lin et al. 2018). Mutations in genes encoding subunits of 
the KEOPS complex lead to decreased  t6A levels and cause 
Galloway–Mowat syndrome (GAMOS, OMIM#251300), 
a rare autosomal recessive condition characterized by the 
association of early onset nephrotic syndrome and micro-
cephaly with central nervous system anomalies (Braun et al. 
2017). Second, the KEOPS complex and Sua5 have been 
identified to promote telomere maintenance, an essential 
process for safeguarding genomic stability (Downey et al. 
2006; Meng et al. 2010). Third, He et al. (2019) identified 
that the KEOPS complex affects both DNA damage response 
(DDR) and repair, especially homologous recombination-
mediated DNA repair, independently of its  t6A synthesis 
function. Very recently, two missense mutations in YRDC 
were associated with GAMOS phenotypes, suggesting over-
lapping functional roles of YRDC and the KEOPS complex 
in cellular processes (Arrondel et al. 2019).
Here, we report on a patient with a severe developmental 
disorder with progeroid features in whom we identified a 
novel causative, homozygous YRDC mutation. Analysis of 
fibroblasts revealed reduced levels of tRNA modification, 
telomere shortening, and impaired DDR.
Results
Clinical report
The index patient II.5 was born after 37 + 0 weeks of ges-
tation to healthy, distantly consanguineous parents from 
northern Iraq origin (Fig. 1). His birth weight was 1740 g 
(− 3.1 SD), his birth length 46 cm (− 1.8 SD), and his head 
circumference (OFC) at birth 29 cm (− 3.6 SD). After birth, 
he developed tonic–clonic seizures and primary liver and 
kidney dysfunction. Newborn screening revealed hypo-
thyroidism (TSH: 996.10 µU/ml; fT3: 0.13 ng/dl) and he 
received intravenous L-thyroxine. He required assisted ven-
tilation. Furthermore, he showed generalized loss of sub-
cutaneous fat with a striking progeroid appearance, hyper-
trichosis, arachnodactyly and adducted thumbs as well as 
facial dysmorphisms including low-set and large appearing 
ears, micro- and retrognathia, long, smooth philtrum, and 
wrinkled skin. He had congenital intestinal malrotation and 
needed surgery due to meconium ileus. After surgery, he 
developed renal failure and intracranial hemorrhage and died 
at the age of 12 days. Family history revealed two healthy 
older sisters, II.2 and II.3, and a brother who died few hours 
after birth (II.1). In addition, the mother had one early mis-
carriage (II.4).
Identification of a homozygous YRDC mutation
Initial genetic testing for progeroid syndromes using a cus-
tom-designed multigene panel including 87 known disease-
associated genes was unremarkable. Therefore, trio whole-
exome sequencing (WES) was performed on DNA extracted 
from blood of the patient II.5 and his unaffected parents, I.1 
and I.2, using the Agilent SureSelectXT Human All Exon 
V7 enrichment kit on an Illumina HiSeq4000 sequencer. We 
analyzed and filtered the trio WES data using the exome 
and genome analysis pipeline “Varbank 2.0” (https:// varba 
nk. ccg. uni- koeln. de/ varba nk2) of the Cologne Center for 
Genomics (CCG, University of Cologne, Germany), and we 
obtained a mean coverage of 60–65 and 96.1–96.3% of target 
were covered more than 10×. Trio-based WES is an effec-
tive diagnostic tool for identification of causative variants in 
individuals with developmental disorders (Palomares-Bralo 
et al. 2017). de novo variants are known to be one of the most 
common genetic causes of developmental disorders (Acuna-
Hidalgo et al. 2016). Both parents of the index patient II.5 
were unaffected, so our analysis included different modes 
of inheritance. We identified only a single heterozygous 
de novo variant, which was excluded as causative variant 
based on population frequency and lacking evidence for 
functional impairment on the affected protein (Supplemen-
tary Table S1). Based on the family history and the reported 
parental consanguinity, we next focused on homozygous 
variants consistent with a recessive transmission. We iden-
tified only one single homozygous variant not present in 
any current database of human genetic variations including 
the gnomAD (https:// gnomad. broad insti tute. org) database 
(last access date 12/01/2021, (Karczewski et al. 2019)) and 
predicted to have a severe impact on protein structure. All de 
novo and rare biallelic or hemizygous variants are listed in 
the supplement (Supplemental Table S1). The homozygous 
missense variant, c.662T > C, was located in exon 4 of the 
YRDC gene (Fig. 1D) and leads to the substitution of an 
evolutionary highly conserved isoleucine at the amino acid 
position 221 by threonine (p.Ile221Thr). The variant was 
predicted as disease-causing by MutationTaster (http:// www. 
mutat ionta ster. org), damaging by SIFT (https:// sift. bii.a- star. 
edu. sg), probably damaging by PolyPhen‐2 (http:// genet ics. 
bwh. harva rd. edu/ pph2), and has a CADD (https:// cadd. gs. 
washi ngton. edu) score of 27.7, indicating deleteriousness 
of this variant. The mutation was embedded in the largest 
autosomal homozygous region (> 5 Mb) determined from 
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the WES data set and was found in heterozygous state in 
both parents. Sanger sequencing was used to validate the 
WES data and to prove that the healthy siblings, II.2 and 
II.3, do not carry the variant in the homozygous state. DNA 
from the deceased brother was not available for genetic test-
ing (Fig. 1B).
Effects of the YRDC mutation on protein stability, 
localization and tRNA modification
To examine the cellular consequences of the p.Ile221Thr 
mutation on protein stability and expression levels, we com-
pared the YRDC protein levels in primary dermal fibroblasts 
Fig. 1  Identification of a homozygous mutation in YRDC in a new-
born with a progeroid phenotype. A Clinical characteristics of the 
index patient II.5 at the age of 5 days. Physical features included gen-
eralized loss of subcutaneous fat with a progeroid appearance, hyper-
trichosis, low-set and large appearing ears, micro- and retrognathia, 
long, smooth philtrum, wrinkled skin, arachnodactyly and adducted 
thumbs. B Family pedigree of the consanguineous family from north-
ern Iraq. Index patient is indicated by arrow. C Electropherograms of 
the identified YRDC mutation (red arrow) confirming homozygous 
state in the affected sibling II.5 and heterozygous carrier status of 
both parents, I.1 and I.2 (MUT mutation, WT wild type). D Schematic 
view of YRDC and localization of the identified mutations. Red arrow 
indicates the YRDC mutation identified within this study, previously 
identified mutations are indicated by black arrows. E Western blot 
analysis was performed on whole-cell lysates from healthy control 
fibroblasts (WT/WT) and patient (II.5)-derived fibroblasts (MUT/
MUT) using anti-YRDC antibody (upper panel). Anti-α-Tubulin anti-
body was used as a loading control (lower panel). F Analysis of sub-
cellular localization of WT (upper panel) and mutant (lower panel) 
YRDC by immunofluorescence staining in patient-derived (MUT) 
and control (WT) fibroblasts using anti-YRDC-antibodies (green). 
Nuclei were counterstained with DAPI (blue). Scale bar, 20  µm. G 
LC–MS/MS-based quantification of  t6A levels in patient-derived 
fibroblasts (MUT) and two different controls (C1 and C2). Technical 
triplicates have been performed on one biological sample each. Lev-
els are shown as MS signal of  t6A divided by UV signal of adeno-
sine. p values were calculated using two-sided t test: *1p = 0.0285, 
*2p = 0.0259
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from patient II.5 and fibroblasts from a matched healthy 
control. Western blot analysis showed comparable expres-
sion levels of YRDC in both control and patient fibroblasts 
(Fig. 1E). Next, we analyzed the subcellular localization of 
wild type (WT) and mutant (MUT) YRDC by immunostain-
ing. YRDC showed a widely diffused intracellular localiza-
tion in both, WT and MUT cells (Fig. 1F). Taken together, 
these data suggest that the missense variant p.Ile221Thr in 
YRDC does not affect its stability or subcellular localization 
in patient fibroblasts.
YRDC has been described to be essential for the synthesis 
of  t6A at position A37 of several tRNAs. To assess the effect 
of the mutation on the level of  t6A in tRNAs, total RNA 
was extracted from patient’s skin fibroblasts and subjected 
to LC–MS/MS analysis. As expected, the global  t6A level of 
the patient showed a significant decrease of 16.3% (Fig. 1G) 
compared to WT samples. This shows that the homozygous 
c.662T > C, p.Ile221Thr mutation in YRDC affects the  t6A 
biosynthesis providing additional functional evidence for 
the causative nature of this homozygous missense mutation.
Q‑FISH‑based evaluation of telomere length
It is well established that telomere shortening and aging-
related processes are strongly associated with each other. 
However, the detailed mechanisms of, e.g., accelerated tel-
omere shortening in monogenic progeria phenotypes are 
largely unknown. Telomere brightness by FISH staining 
has been validated as a solid measure of telomere lengths 
(Ourliac-Garnier and Londoño-Vallejo 2017) with a linear 
brightness-to-telomere relationship (Martens et al. 1998; 
Poon et al. 1999). We, therefore, established and performed 
a novel and highly sensitive in  situ Q-FISH analysis in 
patient fibroblasts (MUT) relying on a 2-step procedure. 
First superresolution STimulated Emission Depletion 
(STED) microscopy was applied to in situ FISH samples 
(Fig. 2A) and used to confirm sufficient spatial separation 
of in situ FISH-labeled telomeres by at least 200 nm. As a 
second step, confocal imaging produced z-stacks of whole 
nuclei, and consequently individual telomeres were iden-
tified and analyzed automatically with image processing 
algorithms (Fig. 2B). Importantly, as a prerequisite for the 
comparative analysis, we have confirmed equal likelihoods 
of telomere detection in all samples regardless of average 
telomere brightness (Fig. 2C). Our analysis of telomere 
brightness revealed a significant decrease (p < 0.01) in tel-
omere brightness in MUT as compared to an age-matched 
control (WT1) and a healthy adult (WT2) (Fig. 2D) with 
both matching numbers of passages. This corresponds to 
on average approximately 26% telomere shortening of chro-
mosomes in patient cells, with shortening being seemingly 
proportional to regular individual telomere lengths. Nota-
bly, we observed a significant increase in the occurrence 
of short (detected as dark) telomeres (Fig. 2E). To further 
analyze whether this telomere shortening is associated with 
increased cellular senescence, we measured the senescence-
associated beta-galactosidase activity in patient and control 
fibroblasts. We observed an increased number of beta-galac-
tosidase-positive patient cells corresponding to a higher pro-
portion of senescent cells (23.7% in patient cells compared 
to 14.5% in control fibroblasts), which in both cases could 
be elevated by approximately 15% by treatment with  H2O2 
(39.6% in patient cells compared to 28.7% in control fibro-
blasts) (Supplementary Figure S2).
Specific gene expression signatures based 
on single‑cell RNA sequencing (scRNA‑seq)
ScRNA-seq can be a powerful tool for analyzing changes in 
gene expression at the cellular level and elucidating novel 
biological mechanisms. To explore the effect of the homozy-
gous p.Ile221Thr mutation in YRDC on the transcriptome, 
we performed single-cell RNA sequencing on patient fibro-
blasts and two sex- and age-matched controls. We used Gene 
Set Enrichment Analysis (GSEA) to determine whether par-
ticular subsets of genes were differentially expressed. Of spe-
cific interest was the finding that among the top 10 enriched 
pathways in YRDC mutant cells we found “Global Genome 
Nucleotide Excision Repair”, “Homology Directed Repair” 
and “HDR through Homologous Recombination (HRR) 
or Single Strand Annealing (SSA)” (Fig. 3) to be altered. 
Even though the normalized enrichment scores were low, 
the prevalence of enriched pathways linked to DNA repair 
mechanisms suggests a possible interaction between YRDC 
function and maintenance of genomic stability. Genome 
instability is a cellular hallmark observed in cells of patients 
with different forms of premature aging syndromes, such 
as Cockayne syndrome, Ataxia–telangiectasia and Bloom 
syndrome (Wu and Hickson 2003; Trapp et al. 2007; Shiloh 
and Lederman 2017). Interestingly, YRDC has very recently 
been identified in CRISPR/Cas9 screens as important for 
DNA damage response in human cells (Olivieri et al. 2020).
Altered DNA damage response (DDR) and DNA 
double‑strand break (DSB) repair
To gain further insight into whether different pathways 
involved in DDR and DNA repair are affected by the iden-
tified mutation in YRDC, we next examined the response 
of patient’s dermal fibroblasts to different genotoxic agents. 
MUT and WT fibroblasts were treated with etoposide, cis-
platin, camptothecin (CPT) or hydroxyurea (HU) and cell 
viability was determined for different timepoints after treat-
ment (Fig. 4A–D). Interestingly, MUT fibroblasts showed 
an increased susceptibility to all employed genotoxic agents 
compared to WT controls, with the strongest effect observed 
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after treatment with cisplatin or CPT (Fig. 4B, C), possibly 
suggesting impaired DNA DSB repair in MUT cells (Dasari 
and Tchounwou 2014).
To further characterize involved DNA repair pathways in 
YRDC mutant cells, we employed automated immunofluo-
rescence microscopy to quantify nuclear γH2AX foci, as a 
surrogate for unrepaired DNA lesions, as well as 53BP1 and 
RAD51 foci, which are markers for non-homologous end 
joining (NHEJ) and homologous recombination (HRR) path-
ways of DSB repair, respectively (Jachimowicz et al. 2019). 
Without treatment, we did not detect any significant differ-
ences in the numbers of γH2AX, 53BP1, and RAD51 foci 
in MUT compared to WT cells. In response to etoposide, we 
observed a significantly delayed clearance of γH2AX foci in 
MUT compared to WT cells (Fig. 4E, left panel). In contrast 
to the etoposide response, MUT cells treated with cisplatin, 
CPT or HU showed a continuous increase in γH2AX foci 
throughout the 24-h observation period compared to WT 
cells (Fig. 4F–H, left panel). Furthermore, MUT cells gen-
erally displayed higher numbers of 53BP1 foci following 
treatment with all four genotoxic agents compared to WT 
cells (Fig. 4E–H, middle panel). This difference was espe-
cially pronounced 24 h after treatment coinciding with high 
levels of γH2AX foci in MUT cells. With the exception of 
Fig. 2  Q-FISH analysis of telomeres in patient fibroblasts and two 
controls. A STED imaging of a TelC-Star-635P FISH-staining (Red-
hot LUT) with DAPI (blue, confocal) counterstain. Z-projection of 
STED imaging confirms that telomeres do not cluster and are dis-
tant enough to be resolved by confocal z-stacks. Scale bar = 2 µm. B 
Thresholder confocal image showing detected telomeres with marked 
center coordinates. Even partially overlapping spots could be resolved 
across a wide range of signal amplitudes. C Detection efficiency for 
telomeres is similar in all experimental groups despite telomere short-
ening, as shown by similar numbers of detected telomeres per cell 
after detection and fit process (n = 66.7 ± 26.8, 68.5 ± 12.7, 63.5 ± 8.9, 
mean ± std). D Telomere brightness is significantly reduced in patient 
fibroblasts (MUT). Each scatter includes the data of 6 nuclei. The 
nuclei of each respective sample had a mean (± std) telomere bright-
ness of 126.3 ± 13.2 (WT1), 93.3 ± 14.4 (MUT), and 132.9 ± 22.0 
(WT2) photon counts. Red lines indicate median and IQR. Stars indi-
cate significance (p < 0.01) by nested one-way ANOVA of log-trans-
formed data, sub grouped by nucleus. E Dark telomeres appear more 
frequently in MUT fibroblasts with altered genetic background. Tel-
omere brightness data follows a lognormal probability function
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etoposide-treated cells, MUT cells also displayed increased 
numbers of RAD51 foci following DNA damage induction 
(Fig. 4E–H, right panel). Corresponding immunofluores-
cence microscopy images are included in the supplement 
(Supplemental Figures S3–S5). Taken together, these results 
combined with the ScRNA-seq data may suggest that the 
homozygous p.Ile221Thr mutation in YRDC confers hyper-
sensitivity to DNA-damaging agents and leads to a global 
DNA DSB repair defect, potentially affecting both HRR and 
NHEJ.
Discussion
Here, we present a patient with a severe developmental dis-
order with progeroid features caused by a novel homozygous 
missense mutation in YRDC. Our functional studies indi-
cate that mutant YRDC results in defective tRNA modifica-
tion, telomere shortening and increased genomic instability, 
thereby, giving first insights into the molecular pathogenesis 
of this novel accelerated aging phenotype.
YRDC is a highly conserved protein interacting with the 
well-described KEOPS complex (Lin et al. 2018). Mutations 
in genes encoding subunits of the KEOPS complex cause 
Galloway–Mowat syndrome (GAMOS, OMIM#251300), a 
rare autosomal recessive condition characterized by the asso-
ciation of early onset nephrotic syndrome and microcephaly 
with central nervous system anomalies (Braun et al. 2017). 
Although patients with mutations in KEOPS share some 
phenotypic features with the individual reported in our study, 
such as, e.g., renal abnormalities or seizures, progeroid 
features as presented by our patient were not observed in 
GAMOS patients with mutations in KEOPS complex com-
ponents. A recently published study reported a family with 
an affected child carrying compound heterozygous YRDC 
mutations (missense mutation (c.251C > T, p.Ala84Val) and 
a 4-base pair deletion leading to a frameshift (c.721_724del, 
p.Val241Ilefs*72)) and a further family with two affected 
children carrying a homozygous in-frame deletion of leucine 
265 (c.794_796del, p.Leu265del) (Arrondel et al. 2019). 
Similar to our patient, all these individuals died early (old-
est age of death 15 months) and they shared some additional 
specific clinical features, such as congenital hypothyroid-
ism, renal failure, and facial dysmorphism. Like our patient, 
the two affected siblings reported by Arrondel et al. showed 
arachnodactyly and primary microcephaly, while these fea-
tures were not present in the single patient of the cited study. 
Arrondel et al. (2019) suggested that mutations in YRDC 
cause an “extremely severe form of GAMOS”. The main 
clinical features are summarized in Table 1. Considering 
the phenotypic overlap of all four patients, we postulate that 
patients with homozygous or compound heterozygous YRDC 
mutations should be viewed as a distinct entity based on the 
specific phenotypic features of congenital hypothyroidism, 
progeroid appearance and premature death.
Our analysis of the functional consequences of the identi-
fied p.Ile221Thr mutation in YRDC indicated that mutant 
YRDC might result in decreased threonylcarbamoylation of 
the N6 nitrogen of the adenosine at the tRNA position 37 
 (t6A). Previous studies have shown that YRDC acts in this 
process together with the KEOPS complex, and mutations 
in KEOPS proteins as well as in YRDC have been linked 
to decreased  t6A levels (El Yacoubi et al. 2009; Srinivasan 
et al. 2011; Perrochia et al. 2013; Lin et al. 2018). The 
reduction of  t6A modifications that we observed in patient-
derived fibroblasts strongly supports causality of the identi-
fied missense variant p.Ile221Thr in YRDC. Still, based on 
the different phenotypic presentation of GAMOS patients 
with mutations in KEOPS proteins and patients with YRDC 
mutations, it is likely that YRDC is involved in additional 
Fig. 3  Whole transcriptome 
analysis based on single-cell 
RNA sequencing reveals 
different gene expression in 
YRDC-mutant fibroblasts. Gene 
Ontology (GO) and Reactome 
enrichment analysis showing 
the top 10 enriched pathways 
in patient fibroblasts compared 
to two sex- and age-matched 
controls. Categories related to 
DNA repair are highlighted in 
dark grey
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cellular processes which are not depending on the KEOPS 
complex.
As we observed progeroid features in our patient, we 
focused on the putative relevance of YRDC in aging pro-
cesses, reflected by its role in telomere maintenance and 
DDR. Arrondel et al. (2019) reported that the telomere 
length in their patients with YRDC mutations was not 
affected. Their results were based on a telomere restriction 
fragment assay and traditional Southern blot analysis, which 
revealed a higher telomere length in affected children com-
pared to their parents. A solid method to measure the tel-
omere length is Q-FISH analysis (Martens et al. 1998; Poon 
et al. 1999; Ourliac-Garnier and Londoño-Vallejo 2017). 
Here, we performed a novel and highly sensitive Q-FISH 
analysis to investigate the impact of mutant YRDC on tel-
omere maintenance. Performing three-dimensional (3D) 
confocal imaging with 200 nm axial step size followed by 
3D image analysis we were able to circumvent most of the 
inherent disadvantages of conventional Q-FISH methods, 
such as, e.g., insufficient separation of adjacent and super-
imposed telomeres and frequent out-of-focus detections 
(Poon et al. 1999). We were able to detect and quantify most 
individual telomeres in the appropriate respective imaging 
planes and thus obtained a remarkable cellular telomere 
coverage of over 70%. This confirms the strength of our 3D 
imaging and analysis approach, resulting in more reliable 
and accurate readout of individual telomere brightness. Our 
analysis revealed a significant decrease in telomere bright-
ness in patient’s fibroblasts, indicating significant telomere 
shortening in the patient cells. This is the first time that 
microscopy-based Q-FISH analysis of individual telom-
eres was used to determine telomere shortening in a human 
progeroid phenotype. Importantly, our data confirms that 
telomeres were detected at same efficiencies in all groups 
regardless of the average telomere brightness, confirm-
ing the robustness of this approach to identify telomeres 
individually in three dimensions. In contrast to the study 
by Arrondel et al., we compared telomere length to an age-
matched control instead of parental control samples, which 
might explain the differences in the age-associated outcome 
of the analyses.
However, the exact mechanistic link between YRDC and 
telomere length remains to be elucidated in comprehensive 
future studies and rescue experiments are required to con-
firm our findings. Some previous studies have speculated 
that the influence of YRDC/Sua5 and the KEOPS com-
plex on telomere length might be attributed to the lack of 
 t6A modification (Daugeron et al. 2011; El Yacoubi et al. 
2011; Perrochia et al. 2013; Huang et al. 2019). In contrast, 
Downey et al. (2006) hypothesized that the KEOPS complex 
promotes both telomere uncapping and telomere elongation. 
Meng et al. (2009, 2010) showed that SUA5 also positively 
regulates telomere maintenance. Liu et al. (2018) supported 
with their results a model in which Sua5 and the KEOPS 
complex are essential for telomere homeostasis independent 
of its t6A biosynthesis activity and suggested that KEOPS 
regulates telomere length by promoting G-overhang gen-
eration. Although its precise action is still elusive, our data 
provides additional support for the assumption that YRDC 
is linked to molecular mechanisms underlying accelerated 
aging processes.
In addition, we analyzed the senescence-associated 
β-galactosidase activity and observed that patient-derived 
fibroblasts show an increased number of β-galactosidase-
positive cells corresponding to a higher proportion of 
senescent cells. Cellular senescence is defined as a stable 
state of cell cycle arrest (Rhinn et al. 2019). Besides the 
well-established role of accumulating senescent cells in 
aging and age-associated conditions, senescence has been 
linked to proper embryonic development (Gal et al. 2021), 
and positive senescence-associated β-galactosidase stain-
ing can be observed at multiple locations in whole-mount 
mice embryos (Muñoz-Espín et al. 2013). Recent studies 
confirmed that cellular senescence contributes to normal tis-
sue patterning and organ development during embryogenesis 
and later in life is essential for tissue repair and regenera-
tion (Gal et al. 2021; Di Micco et al. 2021; Muñoz-Espín 
und Serrano 2014). Accumulation of senescent cells might 
directly impair tissue proliferation (Rhinn et al. 2019) and 
thereby contribute to the severe developmental anomalies 
observed in our patient.
Furthermore, ScRNA-seq revealed an upregulation of 
DDR pathways possibly indicating genomic instability in 
YRDC mutant fibroblasts. Keeping in mind that enrich-
ment scores were low, these results need to be interpreted 
carefully. For validation, we performed additional func-
tional assays using patient fibroblasts. This further analysis 
showed a generally increased susceptibility to DNA-dam-
aging agents and a global DNA DSB repair defect, affect-
ing both HRR and NHEJ. Impairment of DDR mechanisms 
is commonly observed in patients with different progeroid 
syndromes including, e.g., Hutchinson–Gilford progeria syn-
drome, Werner syndrome, or Cockayne syndrome. Interest-
ingly, Braun et al. (2017) observed increased activation of 
DDR pathways resulting in reduced cellular viability after 
knockdown of KEOPS complex subunits, indicating that 
YRDC might contribute to DDR in interaction with the 
KEOPS complex. Our results are consistent with the very 
recently published CRISPR/Cas9 screen, in which Olivieri 
et al. (2020) showed as well that YRDC might be an impor-
tant factor for DNA damage response and thereby promoting 
DNA integrity. Further investigations are required to verify 
this hypothesis.
In summary, our data provides evidence that biallelic 
mutations in YRDC result in a severe developmental disor-
der with progeroid features and might be linked to reduced 
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levels of t6A modifications as well as telomere shortening 
and alteration of DNA damage response.
Methods
Whole‑exome sequencing
Whole-exome sequencing on DNA of the patient II.5 and 
both parents was performed using the Agilent SureSelectXT 
Human All Exon V7 enrichment kit on an Illumina HiSeq 
4000 sequencer. The “Varbank 2” pipeline of the Cologne 
Center for Genomics (CCG) was used to analyze the exome 
data using the following filter criteria: coverage of > 6 reads, 
quality score of > 10, allele frequency ≥ 25%, and a minor 
allele frequency (MAF) < 0.1% in the gnomAD (https:// 
Fig. 4  Homozygous c.662T > C mutation in YRDC confers cellular 
sensitivity to genotoxic agents and a DSB repair defect. A–D Cells 
of the indicated genotypes were treated with etoposide (A), cis-
platin (B), CPT (C) or HU (D) for 96  h and viability was assessed 
by CellTiterGlo (CTG) assays. Error bars represent SD of the mean 
of three technical replicates with > 2000 cells/well. p values were 
calculated using t test with Welch’s correction not assuming equal 
variance. *p < 0.05, **p < 0.01, ***p < 0.001. E–H Cells of the indi-
cated genotype were treated for 2 h with etoposide (150 µM) (E), cis-
platin (20 µM) (F), CPT (2 µM) (G) or with HU (20 mM) (H) and 
stained for γH2AX (left panel), 53BP1 (middle panel) and RAD51 
(right panel). Total number of γH2AX, 53BP1 and RAD51 foci per 
cell were quantified. Dots indicate means of separate replicates; n = 3 
wells; > 2000  cells/well; experiments were independently performed 
three times; two-way ANOVA with Bonferroni’s test. *p < 0.05, 
**p < 0.01, ***p < 0.001
◂
Table 1  Summary of the clinical findings in our patient and the affected individuals with biallelic variants in YRDC reported by Arrondel et al. 
(2019)
+ Present, − Absent, ND Not documented, SD Standard deviation
Reported here Arrondel et al. (2019)
Family A B C
ID Patient 1 Patient 2 Patient 3 Patient 4







Zygosity Homozygous Compound heterozygous Homozygous Homozygous
Exon 4 1/4 4 4
Gender Male Female Male Female
Ancestry Northern Iraq European European
Consanguinity Distantly No Yes
Clinical manifestations
 Birth Born at 37 + 0 weeks ND ND ND
 Birth length 46 cm (− 1.8 SD) ND ND ND
 Birth weight 1740 g (− 3.1 SD) ND ND ND
 Head circumference at 
birth
29 cm (− 3.6 SD) ND ND ND
 Seizures + − − −
 Kidney dysfunction + + + +
 Liver dysfunction + − − −
 Hypothyroidism + + + +
 Facial dysmorphisms Progeroid appearance, 
low-set and large appear-
ing ears, micro- and 
retrognathia, long, smooth 
philtrum, and wrinkled 
skin
+ + +
 Brain anomaly Primary microcephaly Secondary microcephaly Primary microcephaly Primary microcephaly
 Skeletal Arachnodactyly, adducted 
thumbs
− Arachnodactyly Arachnodactyly
 Intestinal malrotation + − − −
 Age at death 12 days 15 months 1.5 months 3 months
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gnomad. broad insti tute. org) database. The following data-
bases were used to obtain gene information: National Center 
for Biotechnology Information (NCBI; https:// www. ncbi. 
nlm. nih. gov), Ensembl Genome Server (http:// www. ensem 
bl. org), UCSC Genome Bioinformatics (http:// genome- euro. 
ucsc. edu) and Genome Aggregation Database (gnomAD; 
http:// gnomad. broad insti tute. org). The variant identified by 
whole-exom sequencing was amplified from DNA of the 
index patient and PCR products were sequenced by Big-
Dye Terminator method on an ABI 3500XL sequencer (Life 
Technologies, Germany). The identified mutation was re-
sequenced in an independent experiment and tested for co-
segregation within the family.
Cell lines and cell cultures
Primary dermal fibroblasts established from patient II.5 and 
respective controls were cultured in Dulbecco’s modified 
Eagle medium (DMEM, Gibco) supplemented with 10% 
fetal calf serum (FCS, Gibco), and antibiotics. All functional 
assays presented in the manuscript were performed using 
cell lines that were matched for passage number and, where 
possible, age as well as sex.
Protein isolation and analysis
Primary dermal fibroblasts were solubilized using ice-cold 
RIPA buffer (10 mM Tris, pH: 8.0; 150 mM NaCl; 1 mM 
EDTA; 1% NP-40; protease inhibitors P 2714 [Sigma-
Aldrich, USA]). The total protein concentration of extracts 
was determined using the BCA Protein Assay Kit (Thermo 
Fisher Scientific, USA). 15–25 µg of total cell lysates were 
separated by Mini-PROTEAN® TGX™ Precast Gels (Bio-
Rad, Germany) and blotted onto nitrocellulose membranes 
(Bio-Rad, Germany). Protein detection was performed 
using an antibody to YRDC (Santa Cruz Biotechnology 
Inc., USA). Secondary antibodies conjugated to peroxidase 
(Santa Cruz Biotechnology Inc., USA) were used and blots 
were developed using an enhanced chemiluminescence sys-
tem, Clarity Max Western (Bio-Rad, Germany), followed 
by detection using the ChemiDoc™ Touch Imaging System 
(Bio-Rad, Germany).
Immunofluorescence stainings and fluorescence 
measurements
For immunofluorescence detection of YRDC, primary der-
mal fibroblasts were grown on coverslips, washed with PBS, 
fixed with 4% paraformaldehyde for 15 min and permeabi-
lized with 1% Triton X-100 for 10 min. Upon blocking for 
30 min with 3% BSA in PBS, slides were incubated with 
YRDC antibodies (1:500, Santa Cruz Biotechnology Inc) 
overnight. Slides were washed with PBS and incubated with 
Alexa Fluor® 488 conjugated goat–anti-rabbit antibodies 
(Thermo Fisher Scientific) for 1 h. Subsequently, slides were 
washed with PBS, mounted in Vectashield with DAPI (H 
1200; Vector Laboratories) and viewed with an Olympus 
FLUOVIEW FV1000 confocal laser scanning microscope.
For automated immunofluorescence microscopy, human 
dermal fibroblasts were seeded onto 96-well plates. For 
RAD51 stainings, cells were additionally pre-extracted in 
sucrose buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 1 mM 
EDTA, 3 mM  MgCl2,300 mM sucrose, 0.5% Triton-X) for 
2 min on ice. Cells were fixed for 10 min in room tempera-
ture with 4% paraformaldehyde, followed by three washes 
with ice-cold 1 × PBS. Subsequently, cells were blocked for 
60 min at room temperature in PBS containing 5% normal 
goat serum (NGS), 2% bovine serum albumin and 0.01% 
Triton X-100. Incubation with the primary antibody was 
performed over night at 4 °C. Incubation with the second-
ary antibody was performed for 1 h at room temperature. 
Analysis was performed as described below in “High-con-
tent screening microscopy.”
Quantification of  t6A modification
500 ng of total RNA per sample was digested to nucleosides 
using 0.6 U nuclease P1 from P. citrinum (Sigma-Aldrich), 
0.2 U snake venom phosphodiesterase from C. adamanteus 
(Worthington), 2 U FastAP (Thermo Scientific), 10 U ben-
zonase (Sigma-Aldrich), 200 ng Pentostatin (Sigma-Aldrich) 
and 500 ng Tetrahydrouridine (Merck-Millipore) in 25 mM 
ammonium acetate (pH 7.5; Sigma-Aldrich) over night at 
37 °C. The nucleosides were then spiked with internal stand-
ard (13C stable isotope-labeled nucleosides from S. cerevi-
siae) and subjected to analysis. 100 ng of digested RNA and 
50 ng internal standard were analyzed via LC–MS [Agilent 
1260 series and Agilent 6460 Triple Quadrupole mass spec-
trometer equipped with an electrospray ion source (ESI)]. 
The solvents consisted of 5 mM ammonium acetate buffer 
(pH 5.3; solvent A) and LC–MS grade acetonitrile (solvent 
B; Honeywell). The elution started with 100% solvent A 
with a flow rate of 0.35 ml/min, followed by a linear gradient 
to 8% solvent B at 10 min and 40% solvent B after 20 min. 
Initial conditions were regenerated with 100% solvent A for 
10 min. The column used was a Synergi Fusion (4 µM par-
ticle size, 80 Å pore size, 250 × 2.0 mm; Phenomenex). The 
UV signal at 254 nm was recorded via a diode array detec-
tor (DAD) to monitor the main nucleosides. ESI parameters 
were as follows: gas temperature 350 °C, gas flow 8 l/min, 
nebulizer pressure 50 psi, sheath gas temperature 350 °C, 
sheath gas flow 12 l/min, capillary voltage 3000 V. The MS 
was operated in the positive ion mode using Agilent Mass-
Hunter software in the dynamic MRM (multiple reaction 
monitoring) mode. For relative quantification, an internal 
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calibration was applied as described previously (Kellner 
et al. 2014).
Single‑cell RNA sequencing (scRNA‑seq)
A full-length, single-cell RNA-seq approach was used with 
the ICELL8 Single-Cell System. Cell suspensions were fluo-
rescently labeled with live/dead stain (DAPI and Texas Red) 
for 15 min prior to their dispensing into the 5184 micro-
chip nanowells (ICELL8 System). After selection of wells 
containing single, live cells, cDNA was synthesized via 
oligo-dT priming in a one-step RT-PCR reaction. P5 index-
ing primers for subsequent library preparation were indexed 
into all wells, with each of the 72 rows on the ICELL8 chip 
receiving a different index, in addition to Terra polymer-
ase and reaction buffer. Transposition enzyme and reaction 
buffer (Tn5 mixture) were dispensed to selected wells, and 
the transposition reaction was performed. P7 indexing prim-
ers were dispensed to wells, with each of the 72 columns on 
the chip receiving a different index. Final Illumina libraries 
were amplified and pooled as they are extracted from the 
chip. Pooled libraries were purified and size selected using 
Agencourt AMPure XP magnetic beads (Beckman Coulter) 
to obtain an average library size of 500 bp. A typical yield 
for a library comprised of ~ 1300 cells was ~ 15 nM. Librar-
ies were sequenced on the HiSeq 4000 (Illumina) to obtain 
on average ~ 0.5 Mio reads per cell (SE; 50 bp).
Data pre‑processing and quality control
Raw sequencing files (bcl) were demultiplexed and fastq 
files were generated using Illumina bcl2fastq software 
(v2.20.0). For data pre-processing, the ICELL8 mappa anal-
ysis pipeline (version 0.9) was run. In brief, mappa_demuxer 
was used to allocate the reads to the cells based on the cell 
barcodes provided in the well-list file. Subsequently, the 
mappa_analyser was used as a wrapper function to perform 
read trimming with cutadapt (version 2.5), genome align-
ment to Homo sapiens genome GRCh38 using STAR (ver-
sion 2.7.2b), read counting for exonic, genomic and mito-
chondrial regions using featureCounts (version 1.6.4) and 
summarization using the R package hanta (version 1.0.0). 
As part of the hanta package, the final matrix of reads counts 
for all genes in all cells underwent quality control (QC) fil-
tering for low expressions using default parameters: (a) for 
cells, only those with at least 10,000 reads associated to 
at least 300 different genes were kept, and (b) for genes, 
only those containing at least 100 reads mapped to them 
from at least 3 different cells were kept. After applying these 
quality control filtering criteria, we analyzed 201 out of 256 
single patient cells and 428 out of 614 single cells of the 
two sex- and age-matched controls. The de-regulated genes 
(abs(log2FolgChange) > 0.25) are listed in the supplement 
(Supplemental Table S2).
Data analysis
For differential expression (DE) analysis between pairs 
of samples, the QC-filtered read count matrix was used as 
input to determine which genes were differentially expressed 
using Wilcoxon Rank Sum and Signed Rank Tests. For the 
individual DE results, a rank score was calculated for each 
gene using the formula rank = − log10(p-value) × log2FC, 
where p value is the raw p value and log2FC is the log2 
fold-change. The ranks were used as input for an enrich-
ment analysis using WebGestaltR (version 0.4.4) for all gene 
ontologies and Reactome pathways.
Cell viability measurement
Cell lines were plated into 384-well plates at densities of 
5000 cells/well. 24 h later, cells were treated with various 
doses of genotoxic chemicals for 96 h. After incubation, 
room-temperature CellTiter-Glo® Reagent (Promega, USA) 
was added 1:1 to each well and the plates were incubated 
at room temperature for 10 min. Luminescence was meas-
ured with the Tecan Infinite M1000 Pro (Tecan, Männedorf, 
CHE) and normalized against control cells treated with vehi-
cle solution. Error bars represent SD of the mean of three 
independent experiments. p values were calculated using t 
test with Welch’s correction not assuming equal variance. 
*p < 0.05, **p < 0.01, ***p < 0.001.
High‑content screening microscopy
High-content screening (HCS) microscopy was performed 
on human dermal fibroblasts using a Thermo Fisher Cel-
lomics ArrayScan XTI with LED light source. Images of 
1104 × 1104 pixels were acquired with a 20 × objective 
(Zeiss) and analyzed using the Cellomics software pack-
age (Colocalization V.4 Bioapplication). Images were back-
ground corrected (3D surface fitting) and DAPI stained cell 
nuclei were identified according to the object selection 
parameters size: 100–1500 μm2, ratio of perimeter squared 
to 4π area: 1–2, length-to-width ratio: 1–5, average intensity: 
400–4000, total intensity: 4 ×  106–2 ×  107. Foci of γH2AX, 
53BP1 and RAD51 were quantified within the nuclear 
region at another excitation wavelength (485 ± 20 nm or 
650 ± 20 nm). Object selection parameters for foci were 
size: 0.1–10 μm2, ratio of perimeter squared to 4π area: 1–5, 
length-to-width ratio: 1–5, average intensity: 500–10,000, 
total intensity: 300–2 ×  106. HCS microscopy results are 
means ± standard deviation; > 2000 cells/well; three tech-
nical replicates were measured per experiment; two-way 
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ANOVA with Bonferroni’s test. *p < 0.05, **p < 0.01, 
***p < 0.001.
Q‑FISH‑based evaluation of telomere length 
from primary dermal fibroblasts
For preparation of cells for Q-FISH analysis, primary cell 
cultures of human dermal fibroblasts were maintained in 
75TC flasks up to passage 5, then split and harvested 48 h 
later at approximately 75% confluency. Therefore, cells were 
trypsinized for 1–2 min, trypsin was neutralized by adding 
media, and cells were pelleted (5 min, 200 g). Supernatants 
were completely removed and 10 ml of pre-warmed (37 °C) 
hypotonic solution (0.0025 M Na citrate, 0.04 M KCl) was 
dropwise added to pellets while vortexing slowly. Cells were 
incubated for 15 min at 37 °C and centrifuged (5 min, 200 g, 
room temperature). Supernatants were partly removed leav-
ing approximately 1 ml in the tubes.
For fixation, cell pellets slowly resuspended by vortex-
ing. 10 ml of cold Carnoy fixative (75% methanol, 25% ace-
tic acid) was added dropwise to the pellets while vortexing 
with increasing speed. Then cells were pelleted at (5 min, 
200 g, room temperature) and supernatants removed leaving 
approximately 1 ml in the tubes. The fixation/centrifugation 
steps were repeated three times. Cells were resuspended in 
a small volume of fixative and cell suspension dropped onto 
clean superfrost slides at optimal ambient humidity. Slides 
were air-dried and spreading efficiencies were checked 
by light microscopy. Slides with cell spreads were dried 
overnight.
Pretreatment slides were rehydrated for 15 min in PBS, 
fixed in 4% formaldehyde in PBS for 4 min at 37 °C, washed 
twice in PBS for 5 min at 37 °C and air-dried. 100 μl of 
RNase A solution (100 µg/ml in 2 × SSC) per slide was 
added and slides were incubated for 1 h at 37 °C in a Ther-
mobrite incubator (a programmable temperature controlled 
slide processing system for FISH procedures). Afterwards 
the slides were washed three times in 2 × SSC and once in 
distilled water. The slides were immersed in 0.005% Pepsin 
for 4 min at 37 °C for protein digestion, washed twice in 
PBS for 3 min at 37 °C and fixed in 4% formaldehyde in 
PBS for 4 min at 37 °C. The slides were washed twice in 
PBS for 5 min at 37 °C (× 2) and once in PBS for 5 min at 
room temperature. Afterwards the slides were sequentially 
dehydrated for 2 min in 70%, 85%, 100% ethanol, respec-
tively, and air-dried.
Denaturation and PNA hybridization
For denaturation and PNA hybridization, slides were placed 
in a pre‐heated Thermobrite at 80 °C for 5 min. 100 μl of 
pre-heated PNA probe (TelC Star635P, 200 nM, Eurogentec) 
in hybridization solution (Oxford Gene Technology) was 
distributed per slide, overlaid with a coverslip and denatured 
at 80 °C for 5 min in the dark. The slides were placed in 
a humidified hybridization chamber at 4 °C overnight for 
PNA probe hybridization (the coverslips were fixed with 
silicon glue).
Afterwards, slides were immersed in washing solution 
(2 × SSC, 1% Tween-20) at room temperature to remove 
the coverslip and silicon glue and washed twice in washing 
solution for 10 min at 55–60 °C, afterwards washed twice in 
2 × SSC and once in distilled water. After drying on air in 
the dark a drop of mounting media (Prolong Gold Antifade 
Reagent with DAPI, Invitrogen) was put onto slide, the slide 
was carefully covered with a coverslip and incubated in the 
dark overnight.
Q‑FISH microscopy
FISH slides were imaged in confocal and STED mode using 
a custom-built setup based on an Olympus IX83 inverted 
microscope with an Abberior QUAD scanner. Slides were 
mounted on a 100 × 1.4 NA oil-immersion objective and 
intact nuclei were identified in the DAPI channel. DAPI and 
TelC-Star635P signals were excited at 405 nm and 633 nm 
excitation wavelengths and recorded with 422–467 nm and 
650–720 nm emission filters, respectively. 3D-Confocal 
imaging was performed at 80 nm × 80 nm–200 nm pixel 
size (x,y,z) at 100 µs pixel dwell time. In addition, single 
frames of imaging planes including bright TelC-Star635P 
signal spots were acquired using STED mode to confirm 
spatial separation of telomeres in confocal imaging.
Q‑FISH image analysis
In ImageJ Fiji, Images were manually masked by the DAPI 
signal to exclude background signals outside nuclei. TelC-
Star635P signals were smoothed by a Gaussian filter with 
σ = 80 nm and subjected to a 3D spot detection routine (Her-
bert et al. 2014) with a background threshold of 25 counts 
and a minimum spot size of 10 voxels. The retrieved center 
of mass coordinates for each telomere spot were used to 
center two orthogonal lateral fits of the signal by a Gauss-
ian function. The better-fit result was used to retrieve tel-
omere brightness from its amplitude, when at least one fit 
was sufficient (r2 > 0.8). No further image or data filtering 
was applied.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00439- 021- 02347-3.
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